Potentiation of cisplatin and carboplatin cytotoxicity by amphotericin B in different human ovarian carcinoma and malignant peritoneal mesothelioma cells

Cancer Chemotherapy and Pharmacology

Volumn 40, Issue 5, 1997, Pages 385-390

  Poulain, Laurent ^a,b   Sichel, François ^a,b   Crouet, Hubert ^b   Bureau, François ^c   Gauduchon, Pascal ^a,b   Gignoux, Marc ^a,c   Le Talaër, Jean Yves ^a,b  

^a UNIVERSITÉ DE CAEN   (France)

^b CENTRE FRANÇOIS BACLESSE   (France)

^c CAEN UNIVERSITY HOSPITAL   (France)

Author keywords

Amphotericin B; Carboplatin; Cisplatin; Malignant mesothelioma; Ovarian carcinoma

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL;

ARTICLE; ASCITES CELL; ATOMIC ABSORPTION SPECTROMETRY; CELL CULTURE; CELL LINE; CONTROLLED STUDY; CYTOTOXICITY; DRUG RESISTANCE; DRUG TUMOR LEVEL; DRUG UPTAKE; HUMAN; HUMAN CELL; IN VITRO STUDY; MALIGNANT MESOTHELIOMA; OVARY CANCER; OVARY CARCINOMA; PRIORITY JOURNAL; TUMOR CELL;

ADENOCARCINOMA; AMPHOTERICIN B; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CISPLATIN; DRUG SYNERGISM; FEMALE; HUMANS; MESOTHELIOMA; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; TREATMENT OUTCOME; TUMOR CELLS, CULTURED;

EID: 0030790666     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050675     Document Type: Article

References (23)

1. Andrews PA, Albright KD (1992) Mitochondrial defects in cis-diamminedichloroplatinum(II)-resistant human ovarian carcinoma cells. Cancer Res 52: 1895
2. Assem M, Bonvalot S, Beltramo JL, Garrido C, Dimanche-Boitrel MT, Genne P, Rebibou JM, Caillot D, Chauffert B (1994) Deleterious effect of serum proteins on the amphotericin B-induced potentiation of cisplatin in human colon cancer cells. Br J Cancer 70: 631
3. Bénard J, Da Silva J, De Blois MC, Boyer P, Duvillard P, Chiric E, Riou G (1985) Characterization of a human ovarian adenocarcinoma line, IGROV1, in tissue culture and in nude mice. Cancer Res 45: 4970
4. Chen G, Zeller WJ (1992) Multiple effects of 3-aminobenzamide on DNA damage by cisplatin (DDP) in DDP-sensitive and -resistant rat ovarian tumor cell lines. Cancer Lett 67: 27
5. Drouhet E, Dupont B (1987) Evolution of antifungal agents: past, present, and future. Rev Infect Dis 9 [Suppl 1]: S4-S14
6. Fram RJ (1992) Cisplatin and platinum analogues: recent advances. Curr Opin Oncol 4: 1073
7. Heidemann HT, Bolten M, Inselmann G (1991) Effects of chronic theophyllin administration on amphotericin B nephrotoxicity in rats. Nephron 59: 294
8. Johnson SW, Ozols RF, Hamilton TC (1993) Mechanisms of drug resistance in ovarian cancer. Cancer [Suppl] 71: 644
9. Kido Y, Khokhar AR, AI-Baker S, Siddik Z (1993) Modulation of cytotoxicity and cellular pharmacology of 1,2-diaminocyclohexane Pt(IV) complexes mediated by axial and equatorial ligands. Cancer Res 53: 4567
10. Kikkawa F, Kojima M, Oguchi H, Maeda O, Ishikawa H, Tamakoshi K, Mizuno K, Kawai M, Suganuma N, Tomoda Y (1993) Potentiating effect of amphotericin B on five platinum anticancer drugs in human cis-diamminedichloroplatinum (II) sensitive and resistant ovarian carcinoma cells. Anticancer Res 13: 891
11. Kojima M, Kikkawa F, Oguchi H, Mizuno K, Maeda O, Tamakoshi K, Ishikawa H, Kawai M, Suganuma N, Tomoda Y (1994) Sensitisation of human ovarian carcinoma cells to cis-diamminedichloroplatinum (II) by amphotericin B in vitro and in vivo. Eur J Cancer 30: 773
12. Liebmann JE, Cook JA, Lipschultz C, Teague D, Fisher J, Mitchell JB (1993) Cytotoxic studies of paclitaxel (Taxol) in human tumor cell lines. Br J Cancer 68: 1104
13. Luke DR, Wasan KM, Verani RR, Brunner LJ, Berens KL, Vadiei K, Lopez-Berestein G (1991) Attenuation of amphotericin B nephrotoxicity in the candidosis rat model. Nephron 59: 139
14. Manetta A, Boyle J, Berman ML, DiSaia PJ, Lentz S, Liao SY, Mutch D, Slater L (1994) Cyclosporine enhancement of cisplatin chemotherapy in patients with refractory gynecologic cancer. Cancer 73: 196
15. Mann SC, Andrews PA, Howell SB (1991) Modulation of CDDP accumulation and sensitivity by forskolin and 3-isobutyl-1-methylxanthine in sensitive and resistant human ovarian carcinoma cells. Int J Cancer 48: 866
16. Masuda H, Tanaka T, Kido A, Kusaba I (1991) Potentiation of cisplatin against sensitive and resistant human ovarian cancer cell lines by AmB. Cancer J 4: 119
17. Morikage T, Ohmori T, Nishio K, Fujiwara Y, Takeda Y, Saijo N (1993) Modulation of cisplatin sensitivity and accumulation by amphotericin B in cisplatin-resistant human lung cancer cell lines. Cancer Res 53: 3302
18. Petru E, Boike G, Sevin BU (1990) Potentiation of cisplatin cytotoxicity by methylxanthines in vitro. J Cancer Res Clin Oncol 116: 431
19. Reed E (1993) Platinum analogs. In: DeVita V, Hellman S, Rosenberg SA (eds) Cancer: principle and practice of oncology, vol 1, 4th edn. Lippincott, Philadelphia, p 390
20. Scudiero DA, Shoemaker RA, Paull KD, Monks A, Tierney S, Nofziger TH, Currens MJ, Seniff D, Boyd MR (1988) Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res 48: 4827
21. Sharp SY, Mistry P, Valenti MR, Bryant AP, Kelland LR (1994) Selective potentiation of platinum drug cytotoxicity in cisplatin-sensitive and - resistant human ovarian carcinoma cell lines by amphotericin B. Cancer Chemother Pharmacol 35: 137
22. Teicher BA, Holden SA, Herman TS, Epelbaum R, Pardee AB, Dezube B (1991) Efficacy of pentoxifyllin as a modulator of alkylating agent activity in vitro and in vivo. Anticancer Res 11: 1555
23. Wilson AP (1984) Characterization of a cell line derived from the ascites of a patient with papillary serous cystadenoma of the ovary. J Natl Cancer Inst 72: 513